Pharmaceutical intermediates

Irinotecan hydrochloride Intermediates

4 pharmaceutical intermediates for Irinotecan hydrochloride. Indication: Colorectal cancer; Non-Hodgkin lymphoma; Non-small cell lung cancer; Lung cancer; Ovarian cancer.

提交项目 All intermediates

About Irinotecan hydrochloride

Originator: Yakult Honsha Co., Ltd
Indication: Colorectal cancer; Non-Hodgkin lymphoma; Non-small cell lung cancer; Lung cancer; Ovarian cancer
Approved Date: 08/05/2010

Available intermediates

4 intermediates currently listed for Irinotecan hydrochloride. Request specifications, documentation or a quotation for any item below.

Irinotecan hydrochloride intermediates
Product Name	CAS No.	Molecular Formula	Physical Properties
1,4'-bipiperidyl	4897-50-1	/	/
1,4'-Bipiperidine-1'-carbonylchloridehydrochloride(1:1)	143254-82-4	/	/
(S)-10-Hydroxycamptothecin	19685-09-7	/	/
7-Ethyl-10-hydroxycamptothecin	86639-52-3	/	/

Other programs under I

Ibrutinib/ Zanubrutinib Iguratimod Imatinib Imeglimin hydrochloride Indacaterol Maleate Infigratinib Ipatacopan Hydrochloride Ipragliflozin

Building toward Irinotecan hydrochloride?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →